Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Cephalon Inc.

(CEPH)

Stuart Levine of Janney Montgomery Scott began coverage with a "buy." He said

Read the full 168 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE